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Abstract
Fistulae represent an important complication in patient 
suffering from Crohn’s disease (CD). Cumulative inci-
dence of fistula formation in CD patients is 17%-50% 
and about one third of patients suffer from recurring 
fistulae formation. Medical treatment options often fail 
and also surgery frequently is not successful. Available 
data indicate that CD-associated fistulae originate from 
an epithelial defect that may be caused by ongoing 
inflammation. Having undergone epithelial to mesen-
chymal transition (EMT), intestinal epithelial cells (IEC) 
penetrate into deeper layers of the mucosa and the gut 
wall causing localized tissue damage formation of a tube 
like structure and finally a connection to other organs or 
the body surface. EMT of IEC may be initially aimed to 
improve wound repair mechanisms since “conventional” 
wound healing mechanisms, such as migration of fibrob-
lasts, are impaired in CD patients. EMT also enhances 
activation of matrix remodelling enzymes such as matrix 
metalloproteinase (MMP)-3 and MMP-9 causing further 
tissue damage and inflammation. Finally, soluble media-
tors like TNF and interleukin-13 further induce their own 
expression in an autocrine manner and enhance expres-
sion of molecules associated with cell invasiveness ag-
gravating the process. Additionally, pathogen-associated 
molecular patterns also seem to play a role for induction 
of EMT and fistula development. Though current knowl-
edge suggests a number of therapeutic options, new 
and more effective therapeutic approaches are urgently 
needed for patients suffering from CD-associated fistu-
lae. A better understanding of the pathophysiology of 
fistula formation, however, is a prerequisite for the de-
velopment of more efficacious medical anti-fistula treat-
ments.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Fistulae represent an important complication 
in Crohn’s disease (CD) patients. CD-associated fistulae 
originate from an epithelial defect due to destructive 
inflammation. Having undergone epithelial-to-mesen-
chymal transition (EMT), intestinal epithelial cells (IEC) 
penetrate into deeper layers of the gut wall causing 
further tissue damage finally forming connections to 
other organs or the body surface. EMT of IEC results in 
activation of matrix remodelling enzymes. Soluble me-
diators like TNF and IL-13 induce their own expression 
and expression of molecules associated with cell inva-
siveness. A better understanding of the pathophysiol-
ogy of fistula formation is a prerequisite for developing 
more efficacious medical anti-fistula treatments.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis are the two 
main forms of  inflammatory bowel diseases (IBD) and 
are characterized by chronic intestinal inflammation. 
An important complication of  CD is the formation of  
fistulae. This frequent clinical problem often causes a 
severely impaired quality of  life in the affected patients. 
According to population-based studies, the cumula-
tive incidence of  fistula formation in CD patients is 
17%-50%[1-3]. About 35% of  patients suffer from at 
least one fistula during their disease course[2]. After 10 
years of  disease, the cumulative incidence for fistulas is 
reported to be up to 33% and after 20 years it is about 
50%[2]. About one third of  patients suffer from recur-
ring fistulae[2]. In roughly 10% of  the CD patients fistu-
lae are the initial disease presentation and may precede 
the manifestation of  intestinal disease by several years[1]. 
Therapeutic options are limited: Medical options include 
antibiotics, immunosuppressives (such as azathioprine or 
cyclosporine) and anti-TNF antibodies. Their clinical ef-
fect is often limited and despite medical treatment more 
than one third of  patients suffers from recurring fistu-
lae[4]. However, also surgical option do not always pro-
vide a definitive solution and permanent fistula closure 
can only be achieved in about 34% of  CD patients[5].
MORPHOLOGICAL CHARACTERISATION 
OF CD FISTULAE
CD fistulae are found perianal in the majority of  cases 
(54%), as well as entero-enteric (24%), recto-vaginal (9%) 
or in other locations, such as entero-cutaneous or en-
tero-vesical[2]. On a histomorphologic level, CD-associat-
ed fistulae reveal a central fissure that penetrates through 
the lamina propria and muscularis mucosa into deeper 
layers of  the underlying gut wall. In general, fistulae are 
lined by granulation tissue consisting of  histiocytes and 
a dense network of  tender capillaries. The lumen is fre-
quently filled up by nuclear debris, erythrocytes as well 
as neutrophils and lymphocytes indicating non-specific 
acute or chronic inflammation. In more than 80% there 
are signs of  moderate to severe acute inflammation. In 
CD fistulae, the wall of  the fistulae is frequently infil-
trated by CD45RO+ positive T-cells, followed by a small 
band of  CD68+ positive macrophages and finally a dense 
infiltrate of  CD20+ B-cells. This is in contrast to non-
CD fistulae, where often an intense infiltration by CD68+ 
macrophages, but only a few CD20+ B-lymphocytes and 
CD45RO+ T-lymphocytes are observed[6].
Independent of  the inflammatory infiltrate about one 
fourth of  CD fistulae feature a lining epithelium central 
in the fistulising inflammation. Depending on the fistula 
location, this lining epithelium consists of  flattened epi-
thelial cells of  the small intestine or colon without goblet 
cells or of  a narrow squamous epithelium in cutaneous 
or perianal fistulae. The cells reveal tight junctions and 
a basement membrane. In “non-epithelialized” fistulae 
some areas are lined with myofibroblast-like cells, so-
called transitional cells (TC). The region where the mu-
cosal epithelial cells transform into the TC is called tran-
sitional zone. The TC are connected by gap junctions to 
each other and in certain areas a new basement mem-
brane develops between TC and the underlying granula-
tion tissue. The TC and the new basement membrane 
are connected by fibronexus. However, in adjacent areas 
there are also disordered myofibroblasts showing no gap 
junctions and a fragmented basement membrane[6]. 
ALTERED MIGRATORY POTENTIAL OF 
COLONIC LAMINA PROPRIA FIBRO-
BLASTS
On a functional level, the migratory potential of  colonic 
lamina propria fibroblasts (CLPF) in the intestine of  CD 
patients is clearly less than in non-IBD or UC patients. 
Of  note, mucosal fibroblasts derived from CD-associated 
fistulae reveal an even further reduced migratory poten-
tial what might contribute to decreased wound healing 
potential in this disease[7,8]. The decrease in the migratory 
potential of  the CLPF can be induced by pro-inflamma-
tory cytokines, such as TNF or IFN and is a persistent 
functional change since it is not reversible even after 
removing the cytokines. Additionally, it is accompanied 
by a decreased expression and phosphorylation, meaning 
activation, of  the focal adhesion kinase (FAK)[7,9] which 
is a central regulator of  cell migration[10]. Fibronectin is 
also an essential factor for the induction of  migration of  
CLPF. In CD fistulae, the ED-A and ED-B isoforms of  
fibronectin are almost absent[11]. This might also critically 
contribute to the reduced migratory potential of  CD 
fistula CLPF, since the ED-A subunit is usually increased 
during wound healing and is an important inducer of  
fibroblast migration[12]. A further stimulator of  CLPF mi-
gration in the intestine is galectin-3 which is secreted by 
colonic epithelial cells[13,14]. Though galectin-3 is able to 
induce the migration of  CLPF derived from CD fistulae, 
its expression is clearly decreased in CD fistulae[14]. These 
observations might explain the reduced mesenchyme-
mediated wound healing potential in patients with CD 
fistulae. Other mechanisms have to step in to repair the 
epithelial barrier. Increased IEC migration is a mecha-
nism aiming to replace the malfunctioning fibroblast 
migration, to improve wound repair and to restore intes-
tinal barrier function. Thus, the migration of  epithelial 
towards the defect might be induced as part of  a com-
pensatory mechanism, since the migratory potential of  
CD fistula CLPF is critically impaired[15]. 
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A KEY ROLE FOR EPITHELIAL TO MES-
ENCHYMAL TRANSITION
In order to migrate, IEC must undergo a conversion into 
mesenchymal-like cells so-called myofibroblasts. This 
process is called epithelial-to-mesenchymal transition. 
During EMT, differentiated IEC characterized by strong 
intercellular junctions and cell polarity lose their epithe-
lial phenotype and acquire a mesenchymal differentiation 
featuring reduced cell-cell contacts and a fibroblast-like 
morphology and function[16,17]. EMT plays an important 
role during embryogenesis and organ development, but 
also for tissue remodelling and wound healing[16-18]. How-
ever, recent studies also suggested that EMT is critically 
involved in pathologic conditions, such as cancer growth 
and fibrosis[16,17]. While TGF is the most potent inducer 
of  EMT in vivo[19], there are further markers for the onset 
of  EMT, such as decreased expression of  E-cadherin 
and b-catenin, translocation of  membrane-bound-
catenin into the cytosol or the nucleus and increased 
expression of  b6-integrin[16,17,20,21].
Available data strongly suggest that EMT might also 
be critically involved in the formation of  the TC layer 
covering the fistula tracts of  CD patients. TGF-1 and 
TGF-2 expression are both upregulated in fistula lining 
cells as compared to regular IEC[22]. E-cadherin is involved 
in the formation of  intercellular zonulae adherentes and is 
found at the lateral cell membrane at the cell-cell contact 
sites of  normal IEC. In the TCs lining the CD fistula tract 
not only a decreased expression, but also redistribution 
of  membranous E-cadherin is detectable. This change 
in localization of  E-cadherin can especially be observed 
in the transition zone[22]. In TC-catenin expression is dif-
fuse, much weaker and found in the cytoplasm and nuclei 
whereas it is located in the lateral cell membrane of  nor-
mal mucosal IEC[22]. Six integrin expression normally is 
restricted to epithelial cells during embryonic development 
and organogenesis. Its re-induction indicates an important 
role of  this molecule during intestinal EMT[20,21]. In con-
trast to normal IEC, TC localised in the transitional zones 
feature a strong staining pattern for 6-integrin[22]. IEC as 
well as mesenchymal-like myofibroblast-like TC expressed 
both of  the epithelial markers, cytokeratin (CK) 8 and CK 
20[22]. These staining patterns of  the TC strongly suggest 
an epithelial origin of  these myofibroblast-like cells that 
show characteristic features of  EMT.
A further event that is characteristic to EMT, is the 
nuclear expression of  the transcription factors SNAIL1 
and SLUG (SNAIL2) which are activated by TGF and 
are involved in the down-regulation of  E-cadherin[16,23,24]. 
Interestingly, there are different expression pattern for 
SNAIL1 and SLUG in CD fistulae. While SNAIL1 is 
heavily expressed in the nuclei of  the TC lining the 
fistula tracts indicating transcriptionally active protein, 
SLUG is mainly detected in cells around the fistula tract 
and only to a very limited level in the fistula tract lin-
ing TC[25]. CLPF from CD patients with fistulae express 
higher SLUG mRNA levels than CLPF from patients 
without fistulae[26]. Expression of  fibroblast growth 
factors 1 and 2 that are also associated with increased 
SNAIL1 expression, reduced E-cadherin expression and 
the onset of  EMT are detectable in the tissue layers be-
low the fistula tract and in the fistula-associated inflam-
matory infiltrates[25]. A number of  EMT characteristic 
events are detectable in and around fistula tracts clearly 
supporting a role for EMT in the pathogenesis of  CD-
associated fistulae. The detection of  epithelial markers 
in submucosal myofibroblast-like cells further supports 
this hypothesis and demonstrates the transformation of  
former IEC into these mesenchymal-like cells.  
INVOLVEMENT OF MATRIX REMODEL-
LING MOLECULES
The intercellular matrix is constantly remodelled by a 
number of  enzymes that degrade all components of  the 
extracellular matrix (ECM), namely the matrix metal-
loproteinases (MMP). Increased MMP activity finally 
results in immune-mediated tissue injury and is associated 
with a number of  pathologies, such as cancer growth and 
CD[27-29]. The importance of  MMPs for the development 
of  CD is highlighted by the fact that in the murine DSS-
induced colitis model, targeted deletion of  MMP-9 has a 
protective effect[30,31] while mice overexpressing MMP-9 in 
the intestinal epithelium develop more severe colitis when 
compared to wild type animals[32]. Further, addition of  
MMP-3 caused extensive tissue injury in an ex vivo human 
fetal model of  intestinal inflammation and tissue injury 
was effectively blocked by inhibiting MMP activity[33]. The 
physiological inhibitors of  MMPs are the tissue inhibitors 
of  MMP (TIMP) which are also secreted by the MMP 
producing cells[27].
In CD fistulae, strong MMP-3 expression is observed 
independent of  the stage of  inflammation. MMP3 mRNA 
and protein expression is detected in mononuclear cells 
and fibroblasts[34]. Inactive and active MMP-9 is expressed 
around CD fistulae and mRNA and protein levels are 
found in granulocytes and fibroblasts[34,35]. The activated 
isoform of  MMP-13 is present in the supernatant of  
untreated CD fistula CLPF, but is almost absent in the su-
pernatant of  non-fistula CLPF. MMP-13 protein expres-
sion also is clearly detectable in mononuclear cells around 
CD fistulae[26,35]. In contrast, expression of  MMP-1 and 
MMP-7 is only weak around CD fistulae, MMP-10 is not 
detectable and MMP-2 protein is equally expressed in 
fistula and control tissue. Activated MMP-2 is only detect-
able in CD fistulae[34]. Protein levels of  TIMP-1, TIMP-2 
and TIMP-3 are low around CD fistulae[34]. These obser-
vations suggest a critical role for matrix remodelling en-
zymes in fistula pathogenesis.
MOLECULES ASSOCIATED WITH CELL 
MIGRATION AND INVASION
The published data on fistula pathogenesis strongly sug-
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gest that fistula originate from an epithelial injury and 
due to defective wound healing mechanisms IEC re-
differentiate into mesenchymal-like cells acquiring mi-
gratory potential. In line with this assumption, molecules 
associated with IEC migration, such as 6-integrin, Ets-1 
transcription factor and the Wnt-inhibitor Dickkopf-
homolog 1 (DKK-1) are detected in CD fistulae.
While regular mucosal epithelial cells do not express 
6-integrin, TC located in the transitional zone are strong-
ly positive for b6-integrin staining[22] and fistula CLPF 
express higher 6-integrin mRNA levels than CLPF from 
control or CD patients without fistulae[26]. These obser-
vations are of  particular interest, since 6-integrin expres-
sion has been associated with migration, invasion, metas-
tasis and shortened survival in certain carcinomas, such 
as colorectal cancer, head-and-neck cancer, breast cancer 
or squamous cell cancer[20,36-39]. Up-regulated b6-integrin 
is associated with increased levels of  EMT[20,38-41], repre-
sents a receptor for fibronectin and tenascin what might 
be important for cell migration, regulates secretion and 
activation of  MMP-9[42,43] and mediates TGF activation 
and adhesion what has also been implicated in increased 
survival, progression and metastases of  various tu-
mours[44,45]. Additionally, 6-integrin can induce its own 
expression in an autocrine manner[46]. On a transcrip-
tional level, 6-integrin is regulated by Ets-1 transcription 
factor[20]. While tissue samples from control and IBD-
patients in remission display only low expression levels 
of  Ets-1 protein, a strong staining signal is detected in 
tissue samples derived from patients with active inflam-
mation and in TC along the fistula tract[47] providing 
further support for the regulatory effect of  Ets-1 on 
6-integrin expression. 
The Wnt-inhibitor DKK-1 represents an important 
factor involved in the regulation of  cell migration. Loss 
of  DKK-1 has been associated with progression of  cer-
tain types of  carcinomas, such as CRC[48]. The secreted 
glycoprotein is capable to block IEC migration, is a po-
tent antagonist of  the canonical Wnt/b-catenin signal-
ling pathway and has been implicated to act as a media-
tor of  inflammation[49,50]. In the intestinal tissue of  non-
IBD control patients, Dkk-1 staining is very weak, while 
tissue samples from CD-patients with a perianal fistulae 
reveal strong DKK-1 staining in TC lining the fistula 
tracts and patients with active CD also exhibit consider-
able DKK-1 expression in inflammatory infiltrates[51].   
TGF
TGF is the most important inducer of  EMT[19] and ex-
pression of  TGF-1 and TGF-2 is higher in TC than in 
normal IEC[22]. TGF induces the mRNA expression of  
interleukin-13 (IL-13) in the HT-29 IEC spheroid model 
of  EMT and the secretion of  IL-13 from fistula CLPF, 
but not from CLPF from non-IBD control patients 
or CD patients without fistulae[26]. The effect of  TGF 
on IL-13 expression in IEC is mediated via -catenin 
and DKK-1[51]. In HT-29 IEC, TGF treatment induces 
DKK-1 levels and this effect is inhibited by knock-down 
of  -catenin. Interestingly, knock-down of  either-catenin 
or DKK-1 prevents the TGF-induced increase in IL-13 
expression[51]. These observations fit to the nuclear stain-
ing pattern of  -catenin in TC. Increased TGF levels in 
TC induce nuclear accumulation, meaning transcrip-
tional activation, of  -catenin what results in enhanced 
expression of  DKK-1 and IL-13. The TGF-induced up-
regulation of  DKK-1 might serve hereby as a negative 
feed-back mechanism to control TGF-mediated effects. 
However, IL-13 decreases the expression of  DKK-1 in 
IEC and fistula CLPF[51] what finally dis-ruptures this 
regulatory mechanism and might result in uncontrolled 
secretion of  IL-13.
IL-13
IL-13 has been implicated in the pathogenesis of  tissue 
fibrosis, such as in the lung or liver, and, in this context, 
induces the secretion of  TGF[52-54]. It is mainly secreted 
by Th2-cells and its alpha 1 receptor (IL-13R1) is the 
signal transducing receptor while the alpha 2 recep-
tor (IL-13R2) acts as a decoy receptor[55,56]. In TC lining 
the fistula tracts as well as in deformed crypts adjacent 
to the fistula, IL-13 and IL-13R1 are heavily expressed, 
while they are almost absent in the intestine of  non-IBD 
patients, UC patients and CD patients without fistula 
regardless their inflammation status[26]. These observa-
tions suggest that IL-13 expression and associated ef-
fects might be induced in CLPF and fistula-associated 
IEC in a positive feedback mechanism. On a functional 
level, IL-13 induces the expression of  SLUG and 6-in-
tegrin in HT29 cells grown as monolayers or spheroids. 
Interestingly the IL-13 induced 6-integrin expression is 
mediated, at least in part, via SLUG transcription factor 
and SLUG expression is sensitive to anti-IL-13 antibody 
treatment. However, in contrast to TGF, IL-13 treatment 
is not sufficient to induce EMT in the HT29-IEC spher-
oid model[26]. 
TNF
TNF has been demonstrated to induce EMT in IEC and 
is able to induce the expression of  TGF[47,57,58]. Similar to 
IL-13, strong staining for TNF and its receptor, TNF-
receptor I (TNF-RI) is detected in TC lining the fistula 
tracts as well as in IEC of  adjacent crypts in CD patients. 
TNF is also expressed in fistula surrounding immune 
cells[25]. This observation further supports the hypothesis 
that TNF, similar to IL-13, induces its expression in an 
autocrine manner. Correlating, TNF induces its own 
expression in IEC and fistula CLPF in vitro[47,57]. In IEC 
and CLPF, TNF stimulates the expression of  6-integrin 
and Ets-1 transcription factor and knock-down of  Ets-1 
results in diminished 6-integrin levels in response to 
TNF. Of  note, while TNF induces TGF and EMT in 
IEC, it is not sufficient to stimulate IL-13 neither in IEC 
nor in fistula CLPF[47]. These observations suggest that 
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TNF, which is naturally present in acutely and chroni-
cally inflamed intestinal tissue, acts via two different 
pathways: TNF induces EMT on the one hand by its 
own, on the other had via TGF, as part of  a wound heal-
ing mechanism. However, aberrant responses of  IEC 
and/or CLPF to TGF then result in increased expres-
sion of  IL-13. IL-13, similar to TNF, then stimulates its 
own expression via a positive feedback mechanism what 
finally causes the expression of  molecules being associ-
ated with cell migration and invasiveness, such as Ets-1 
and 6-integrin. TNF-induced effects can be effectively 
blocked by administration of  an anti-TNF antibody in 
vitro[47], what might also explain, at least in part, the ben-
eficial effect of  anti-TNF antibodies for fistula treatment 
in CD patients.
PATHOGEN-ASSOCIATED MOLECULAR 
PATTERN
Polymorphisms within the nucleotide oligomerization 
domain 2 (NOD2) gene are associated with a fistulizing 
disease course of  CD[59]. The bacterial wall component 
and pathogen-associated molecular pattern (PAMP), 
muramyl-dipeptide, is the natural ligand for NOD2 and 
following activation of  NOD2, immune cells produce 
pro-inflammatory cytokines, such as TNF[60]. MDP treat-
ment induces the expression of  genes being associated 
with EMT as well as with cell invasiveness, such as TGF, 
SNAIL1, IL-13 and 6-Integrin, in IEC. While in non-
fistula CLPF, MDP significantly induced mRNA expres-
sion of  Ets-1, 6-Integrin, TNF, SNAIL1 and TGF, in 
fistula CLPF MDP treatment only induces mRNA levels 
of  Ets-1 and TGF[47]. Since fistula CLPF express high 
levels of  TNF and IL-13 via an autocrine mechanism, 
it might be that exogenous stimulation of  these cells, 
i.e., by MDP, is not sufficient to further induce TNF or 
IL-13 levels in these cells. Interestingly, lipopolysaccha-
ride (LPS) does not induce any of  the fistula-associated 
molecules in either IEC or CLPF pointing towards a 
specific role for the MDP-NOD2 axis in fistula patho-
genesis. These observations suggest that distinct PAMPs 
might play a critical role for fistula pathogenesis by in-
ducing EMT and genes being associated with EMT and 
cell invasiveness what makes the use of  antibiotics in 
fistula treatment plausible.
CONCLUSION
Taken together, available data demonstrate that CD-
associated fistulae originate from an epithelial defect that 
occurs during chronic inflammation. Having undergone 
EMT, IEC penetrate into deeper tissue layers causing 
tissue damage and a connection to other organs or the 
body surface. EMT of  IEC is part of  a wound repair 
mechanism as inflammation causes ongoing tissue dam-
age and conventional wound healing mechanisms, such 
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Figure 1  Pathogenesis of Crohn’s disease-associated fistulae. An epithelial barrier defect favours the invasion of pathogen-associated pattern (PAMPs) into the 
gut mucosa (1). On the one hand, for wound healing purposes, intestinal epithelial cells undergo epithelial-to-mesenchymal transition (2). On the other hand, presence 
of PAMPs induced an inflammatory reaction resulting in increased secretion of TNF (3). TNF is able to induce secretion of TGF as well as to induce EMT and expres-
sion of molecules associated with cell invasiveness, such as 6-integrin. TGF-induced IL-13 and elevated activation of matrix remodelling MMPs critically contribute to 
invasive cell growth (4). Finally, EMT, MMP over-activation and elevated expression of invasive molecules contribute to the development of fistulae (5).
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as migration of  fibroblasts, are impaired. The expression 
of  EMT-associated molecules results in enhanced activa-
tion of  matrix remodelling enzymes such as MMP-3 and 
MMP-9 causing further tissue damage and inflamma-
tion. Finally, soluble mediators such as TNF and IL-13 
promote their own expression in an autocrine manner 
and enhance expression of  molecules being associated 
with cell invasiveness. Subsequently, fistula formation 
and “growth” is constantly promoted and further sup-
ported by the presence of  EMT-inducers, such as TGF, 
and PAMPs (Figure 1). Though current knowledge sug-
gests a number of  therapeutic options, new and more 
effective therapeutic approaches are urgently needed for 
patients suffering from CD-associated fistulae.
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